Aprameya Engineering Q2 FY26 Share Price & Earnings Call Analysis
- Market cap
- ₹194 Cr
- P/E
- 38.53
- ROE
- 7.54%
- PEG
- -15.00
- Price to sales
- 3.54
- Debt to equity
- 0.10
- 52W high / low
- ₹353 / ₹79.6
- Sales growth (5Y)
- 16.12%
- EBITDA margin
- 19.01%
- Net profit margin
- 9.21%
- Promoter holding
- 74.05%
- Sales (last year)
- ₹55 Cr
Incorporated in September 2003, Aprameya Engineering Limited specializes in installing and maintaining Intensive Care Units (ICU), Neonatal Intensive Care Units (NICU), Pediatric Intensive Care Units (PICU), Operation Theatres, and prefabricated structure wards in hospitals and medical care centers.[1]
Guidance scorecard · Q2 FY26 call
What Aprameya Engineering Ltd's management guided
and where it ranks in Healthcare Equipment & Supplies
Healthcare Equipment & Supplies
RevenueQ4 FY25 call
10–20%- Aprameya aims to achieve sustained growth faster than the healthcare infrastructure industry's CAGR of 22% over the last decade.
- The company is optimistic about securing good orders across multiple states due to its proprietary products and strong entry barriers in tenders.
- With an expanding geographic footprint into states like Bihar, Uttarakhand, Assam, Chhattisgarh, Daman, and Sikkim, Aprameya is positioned for scalable growth.
- Order book stood at INR 60 crores, with expectations for continuous order inflow driven by unique, lifesaving proprietary solutions.
2 more points from Aprameya Engineering Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ4 FY25 call
FlatSee what Aprameya Engineering Ltd said on margins — free account, 30 seconds.
CapexQ4 FY25 call
Planned- Capex for expansion into new states will be gradual, not a one-time large investment; focus is on brownfield projects (working inside existing buildings) rather than greenfield projects.
- Capital investments in new states will be phased over 2-3 months per project rather than upfront heavy capital.
- The company plans to control capex carefully to avoid hampering cash flow and maintain a balanced inflow and outflow ratio.
- Specific capex figures are not shared publicly; investors are encouraged to contact the IR agency for detailed queries.
2 more points from Aprameya Engineering Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ4 FY25 call
PlannedSee what Aprameya Engineering Ltd said on fundraising — free account, 30 seconds.
Order bookQ4 FY25 call
Rising- Current order book: Approximately INR 60 crores.
- Execution timeline: Orders expected to be completed within 5 to 6 months.
- Geographic split: 60%-70% from Maharashtra, 10%-20% from Rajasthan, remaining from Gujarat.
- Growth outlook: Company optimistic about securing additional orders due to sector growth and strong entry barriers.
2 more points from Aprameya Engineering Ltd's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Equipment & Supplies
on management's own guidance
- Strong growth2
- Strong growth1
- Q-Line BiotechGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Healthcare Equipment & Supplies companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Flat | ₹627 Cr | 21.4 | |
| 2 | 40%+ | Flat | ₹147 Cr | 16.8 | |
| 3 | Q-Line Biotech | 20–40% | Up 2%+ | ₹1,467 Cr | 25.9 |
| 4 | 20–40% | Flat | ₹18,144 Cr | 83.6 | |
| 5 | 20–40% | Flat | ₹173 Cr | 35.0 | |
| 6 | 10–20% | Up 2%+ | ₹170 Cr | 18.8 |
Sign up free to see every company in the sector ranking and track Aprameya Engineering Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Healthcare Equipment & Supplies rankingFinancials of Aprameya Engineering Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Aprameya Engineering Ltd
Quarterly Results
Quarter-by-quarter operating performance
Financials of Aprameya Engineering Ltd
Profit & Loss
Annual income statement trend
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|
| Sales + | 12 | 26 | 35 | 78 | 65 | 136 | 169 |
| Expenses + | 11 | 24 | 25 | 69 | 59 | 111 | 132 |
| Operating Profit | 2 | 2 | 10 | 9 | 6 | 24 | 37 |
| OPM % | 13% | 9% | 29% | 12% | 10% | 18% | 22% |
| Other Income + | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Interest | 1 | 1 | 0 | 2 | 2 | 3 | 4 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 1 | 2 | 10 | 7 | 5 | 22 | 33 |
| Tax % | 8% | 44% | 25% | 28% | 24% | 26% | |
| Net Profit + | 1 | 1 | 7 | 5 | 3 | 16 | 25 |
| EPS in Rs | 10.66 | 3.84 | 2.49 | 8.47 | 12.92 | ||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Aprameya Engineering Ltd
Balance Sheet
Capital structure and asset base
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 7 | 14 | 14 | 19 | 19 |
| Reserves | 0 | 0 | 7 | 6 | 9 | 45 | 52 |
| Borrowings + | 4 | 1 | 14 | 29 | 42 | 30 | 37 |
| Other Liabilities + | 6 | 5 | 20 | 13 | 10 | 49 | 26 |
| Total Liabilities | 14 | 11 | 49 | 62 | 76 | 144 | 135 |
| Fixed Assets + | 1 | 1 | 2 | 1 | 1 | 1 | 1 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 13 | 10 | 47 | 60 | 74 | 143 | 133 |
| Total Assets | 14 | 11 | 49 | 62 | 76 | 144 | 135 |
Financials of Aprameya Engineering Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 0 | 4 | 10 | -13 | -10 | -11 |
| Cash from Investing Activity + | -1 | 0 | -0 | -2 | -1 | -0 |
| Cash from Financing Activity + | 1 | -4 | -8 | 13 | 11 | 11 |
| Net Cash Flow | 0 | -0 | 2 | -2 | 0 | -0 |
| Free Cash Flow | -0 | 4 | 10 | -14 | -11 | -11 |
| CFO/OP | 22% | 173% | 149% | -115% | -133% | -28% |
Financials of Aprameya Engineering Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 182 | 58 | 278 | 195 | 325 | 320 |
| Inventory Days | 245 | 122 | 455 | 376 | 74 | |
| Days Payable | 269 | 147 | 1,100 | 415 | 146 | |
| Cash Conversion Cycle | 159 | 33 | -367 | 157 | 253 | 320 |
| Working Capital Days | 40 | 36 | 200 | 116 | 153 | 166 |
| ROCE % | 35% | 59% | 25% | 12% | 31% |
Continue your research
What Aprameya Engineering Ltd's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- Galaxy Medicare (Q2 FY27)
Revenue from Operations (₹ Mn): . Key investor presentation takeaways from Galaxy Medicare's Q2 FY27 investor presentation — and how it ranks against sector pee
- Nureca Ltd (Q2 FY27)
Year-on-year growth in revenue from operations: approximately 55% increase (585.99 vs 378.41 million standalone) . Key results statement takeaways from Nureca's
- Nureca Ltd (Q2 FY26)
Q2 FY26 Revenue from Operations: INR 528 million, a 7% year-on-year (YoY) growth from INR 493 million in Q2 FY25. Key investor presentation takeaways from Nurec
- QMS Medical Allied Services Ltd (Q3 FY26)
Q3FY26 Revenue from Operations: ₹37.3 crore . Key investor presentation takeaways from QMS Medical Allied Services Ltd's Q3 FY26 investor presentation — and how